Table 1.
Clinical characteristic | All TCGA HNSC |
OPSC-CR |
||
---|---|---|---|---|
Ratio of ERα mRNA (95% CI) | P * | OR for ERα-positive/negative (95% CI) | P * | |
HPV status | ||||
Negative | 1.00 (Referent) | 1.00 (Referent) | ||
Positive | 3.71 (2.57 to 5.36) | <.001 | 4.04 (1.26 to 13.01) | .02 |
N classification | ||||
<N2b | 1.00 (Referent) | 1.00 (Referent) | ||
≥N2b | 0.75 (0.57 to 0.98) | .04 | 1.85 (0.97 to 3.54) | .06 |
Sex | ||||
Male | 1.00 (Referent) | 1.00 (Referent) | ||
Female | 1.17 (0.91 to 1.50) | .22 | 2.00 (0.87 to 4.60) | .1 |
Primary site tonsil | ||||
No | 1.00 (Referent) | 1.00 (Referent) | ||
Yes | 0.90 (0.57 to 1.43) | .66 | 1.44 (0.75 to 2.75) | .27 |
Smoker | ||||
Never | 1.00 (Referent) | 1.00 (Referent) | ||
Ever | 0.76 (0.59 to 0.98) | .03 | 0.73 (0.37 to 1.44) | .36 |
Age, y | ||||
≤60 | 1.00 (Referent) | 1.00 (Referent) | ||
>60 | 1.04 (0.84 to 1.29) | .70 | 1.21 (0.60 to 2.44) | .59 |
Metastasis at presentation | ||||
No | 1.00 (Referent) | 1.00 (Referent) | ||
Yes | 0.80 (0.31 to 2.07) | .65 | 0.88 (0.26 to 2.91) | .83 |
T classification | ||||
T≤2 | 1.00 (Referent) | 1.00 (Referent) | ||
T >2 | 1.17 (0.90 to 1.52) | .25 | 0.92 (0.45 to 1.87) | .82 |
Alcohol abuse | ||||
No | — | — | 1.00 (Referent) | |
Yes | 0.83 (0.34 to 2.04) | .69 | ||
Keratinizing tumor | ||||
No | — | — | 1.00 (Referent) | |
Yes | 0.45 (0.20 to 0.99) | .048 |
P values were calculated using two-sided Wald tests. For The Cancer Genome Atlas (TCGA) head and neck squamous carcinoma (HNSC) cohort, multiple linear regression of log-transformed mRNA levels against the indicated variables; relationships with clinical variables are expressed as mRNA expression ratios on the nontransformed scale. For oropharyngeal squamous carcinoma chemoradiation (OPSC-CR) cohort, multiple logistic regression of positive/negative immunohistochemical staining against the indicated variables. CI = confidence interval; ERα = estrogen receptor α; OR = odds ratio.